Women over 40 are the primary audience for maca root marketing, largely because this age range overlaps with perimenopause. This article looks specifically at what the evidence suggests for this age group and what additional considerations apply.
Why This Age Group Is the Research Focus
Many maca trials specifically recruited perimenopausal or postmenopausal women, which typically means women in their 40s and 50s, making this the age group with the most directly applicable research rather than an incidental marketing choice.
Benefits Suggested by the Research for This Group
For women over 40, the most consistent trial findings relate to self-reported libido and psychological symptoms during the menopausal transition, including mood and anxiety scores. As covered elsewhere, hot flash results specifically have been inconsistent across studies, so this should not be the primary reason to try maca.
Medication Interactions More Common at This Age
Women over 40 are statistically more likely to be managing conditions like hypothyroidism, taking hormone therapy, or using anticoagulant medication for cardiovascular risk factors that become more common with age, all of which have specific interaction considerations with maca covered in dedicated articles on this site. This makes a pre-use conversation with a healthcare provider more relevant for this age group than for a younger, generally healthier population.
Bone Density and Broader Health Context
Because bone density and cardiovascular risk become more clinically relevant after 40, particularly around the menopausal transition, maca should be considered one small piece of a broader health picture that includes calcium and vitamin D status, weight-bearing exercise, and regular checkups, rather than a standalone solution to age-related health changes.
How Much Research There Actually Is
The clearest summary of the menopausal symptom evidence is a 2011 systematic review that searched 17 databases and found only four randomized trials comparing maca with placebo, in healthy perimenopausal, early postmenopausal and late postmenopausal women. All four reported favorable effects on standard menopause symptom scores, the Kupperman Index and the Greene Climacteric Scale[1].
The reviewers still called the evidence limited. The number of trials, the total sample size and the average quality were too low for firm conclusions, and they noted that maca’s safety had not yet been proved and should be tested in larger studies[1].
What Two Small Crossover Trials Measured
Two frequently cited trials in this age group were small crossovers, in which each woman took maca for six weeks and placebo for six weeks. In 14 postmenopausal women who completed the first, 3.5 g of maca a day reduced psychological symptoms, including anxiety and depression, and sexual dysfunction scores compared with placebo. Blood estradiol, FSH, LH and SHBG did not change[2].
A follow-up in 29 postmenopausal women in Hong Kong, taking 3.3 g a day, again found no change in estradiol, FSH, SHBG or thyroid-stimulating hormone, and no change in glucose or blood lipids, but lower depression scores and lower diastolic blood pressure. The authors cautioned that cultural differences in how symptoms are reported might play a part[3]. Six weeks is short, and neither trial can say what happens over years of use.
What This Means for Common Concerns After 40
The unchanged hormone and TSH results are reassuring in a narrow sense, and they are also why maca should not be thought of as a hormone treatment. They come from a few dozen women over six weeks, so they do not settle questions about thyroid conditions or long-term use. Those are covered in our article on maca and thyroid health and our guide to maca and medications. The blood pressure result is one small finding, not a reason to change any blood pressure treatment; the details are in our article on maca and blood pressure.
For sexual function, a 2018 meta-analysis of plant compounds in menopausal women listed maca among the preparations that significantly improved sexual function, while soy and red clover did not[4]. Because the pool of maca trials in women is small[1], that is one more signal pointing the same way rather than independent proof.
Frequently Asked Questions
Why is maca marketed so heavily to women over 40?
This age group overlaps with perimenopause, which is also the population most represented in maca’s clinical trial research, making the marketing focus at least partly grounded in the actual research base.
Are there extra precautions for women over 40 taking maca?
Yes. This age group is more likely to be managing thyroid conditions, taking hormone therapy, or using blood thinners, all of which have documented interaction considerations with maca.
Should maca replace other health priorities after 40?
No. Maca should be considered a small addition alongside, not a replacement for, broader health priorities like bone density support, cardiovascular health, and regular medical checkups.
References
- Maca (Lepidium meyenii) for treatment of menopausal symptoms: A systematic review. Maturitas, 2011
- Beneficial effects of Lepidium meyenii (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content. Menopause, 2008
- Maca reduces blood pressure and depression, in a pilot study in postmenopausal women. Climacteric, 2015
- Effect of phytoestrogens on sexual function in menopausal women: a systematic review and meta-analysis. Climacteric, 2018
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.




